Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists

The present report describes the effect of mGluR agonists and antagonists administration on phospholipase C activation by measuring accumulation of [ 3H] inositol monophosphates (IP) in rats pre-labeled with [ 3H] myo-inositol (i.c.v. 24 h pre-treatment). The levels of accumulated [ 3H]IP were then...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain research 1999-03, Vol.821 (2), p.539-545
Hauptverfasser: Johnson, Michael P, Chamberlain, Maryjo, Kelly, Gerard M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 545
container_issue 2
container_start_page 539
container_title Brain research
container_volume 821
creator Johnson, Michael P
Chamberlain, Maryjo
Kelly, Gerard M
description The present report describes the effect of mGluR agonists and antagonists administration on phospholipase C activation by measuring accumulation of [ 3H] inositol monophosphates (IP) in rats pre-labeled with [ 3H] myo-inositol (i.c.v. 24 h pre-treatment). The levels of accumulated [ 3H]IP were then determined from clarified tissue homogenates using ion-exchange chromotography. Following lithium chloride treatment (10 mg/kg, s.c.), (R/S)-3,5-dihydroxyphenylglycine (DHPG), a selective group I mGluR agonist was found to dose-dependently cause a maximal increase in the levels of [ 3H]IP at 0.3 to 3 μmol/8 μl i.c.v. with lower doses resulting in less efficacious or no responses. This effect was temporal-dependent reaching a plateau at 2 h. The DHPG-induced increases in [ 3H]IP were most pronounced in the hippocampus where a 3- to 5-fold increase above vehicle was consistently found, but significant approximately 2-fold increases were also seen in the cerebellum, striatum and frontal cortex. The mixed group I and II agonist, (1S,3R)-1-aminocyclopentane- trans-1,3-dicarboxylic acid (1S,3R- t-ACPD), similarly resulted in dose-dependent increases in [ 3H]IP levels with doses of 1 to 3 μmol i.c.v. Furthermore, this effect was enantiomer specific since the less active 1R,3S- t-ACPD failed to alter phosphoinositol hydrolysis. Administration of the selective mGluR5 agonist (R/S)-2-chloro-5-hydroxyphenyl-glycine (CHPG) resulted in a dose-dependent increase in hippocampal but not cerebellar levels of [ 3H]IP, consistent with the receptor distribution of the two group I mGluRs. The Group II agonist LY354740 (1S,2S,5R,6S-2-aminobicycl[3.1.0]hexane-2,6-dicarboxylate monohydrate) and the group III agonist L-AP 4 (L-(+)-2-amino-4-phosphonobutyric acid) failed to alter the levels of [ 3H]IP. LY341495 (2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid) is a nM potent Group II antagonist. However, LY341495 has also been found to have μM potency in inhibiting mGluR1 and 5. The stimulation of [ 3H]PI hydrolysis by 1 μmol DHPG was dose-dependently blocked by co-administration of the mGluR antagonists, LY341495 at doses that are constant with an interaction at Group I mGluR's. Taken together these results suggest that stimulation of group I mGluRs results in measurable increases in PI hydrolysis in vivo. This method could be quite useful in determining the doses and routes of administration of agonists and antagonists that are required to interact with group
doi_str_mv 10.1016/S0006-8993(99)01065-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69607306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006899399010653</els_id><sourcerecordid>69607306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-4cd17b080b021316e4ff75e13ec565baa27b761047fc8b8a825aedd96b897cf93</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EotvCTwD5gFA5BOw4tuNThSo-KlUCCThwshxnsmuUxMHjLNp_j9tdATdOo9E8M_PqIeQZZ6854-rNF8aYqlpjxKUxrxhnSlbiAdnwVteVqhv2kGz-IGfkHPFHaYUw7DE542XQtE2zId8_7yIuuxjmiCGHHuju0Kc4HjAgDTPdh32kv0Le0W2K60Jv6ATZdTGnuARPt-Oa3eQy0AQelhwTdds4B8z4hDwa3Ijw9FQvyLf3775ef6xuP324uX57W_mSJVeN77nuWMs6VnPBFTTDoCVwAV4q2TlX604rzho9-LZrXVtLB31vVNca7QcjLsjL490lxZ8rYLZTQA_j6GaIK1plFNOCqQLKI-hTREww2CWFyaWD5czeObX3Tu2dMGuMvXdqRdl7fnqwdhP0_2wdJRbgxQlw6N04JDf7gH85XUsp64JdHTEoNvYBkkUfYPbQhyIv2z6G_yT5DQxllN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69607306</pqid></control><display><type>article</type><title>Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Johnson, Michael P ; Chamberlain, Maryjo ; Kelly, Gerard M</creator><creatorcontrib>Johnson, Michael P ; Chamberlain, Maryjo ; Kelly, Gerard M</creatorcontrib><description>The present report describes the effect of mGluR agonists and antagonists administration on phospholipase C activation by measuring accumulation of [ 3H] inositol monophosphates (IP) in rats pre-labeled with [ 3H] myo-inositol (i.c.v. 24 h pre-treatment). The levels of accumulated [ 3H]IP were then determined from clarified tissue homogenates using ion-exchange chromotography. Following lithium chloride treatment (10 mg/kg, s.c.), (R/S)-3,5-dihydroxyphenylglycine (DHPG), a selective group I mGluR agonist was found to dose-dependently cause a maximal increase in the levels of [ 3H]IP at 0.3 to 3 μmol/8 μl i.c.v. with lower doses resulting in less efficacious or no responses. This effect was temporal-dependent reaching a plateau at 2 h. The DHPG-induced increases in [ 3H]IP were most pronounced in the hippocampus where a 3- to 5-fold increase above vehicle was consistently found, but significant approximately 2-fold increases were also seen in the cerebellum, striatum and frontal cortex. The mixed group I and II agonist, (1S,3R)-1-aminocyclopentane- trans-1,3-dicarboxylic acid (1S,3R- t-ACPD), similarly resulted in dose-dependent increases in [ 3H]IP levels with doses of 1 to 3 μmol i.c.v. Furthermore, this effect was enantiomer specific since the less active 1R,3S- t-ACPD failed to alter phosphoinositol hydrolysis. Administration of the selective mGluR5 agonist (R/S)-2-chloro-5-hydroxyphenyl-glycine (CHPG) resulted in a dose-dependent increase in hippocampal but not cerebellar levels of [ 3H]IP, consistent with the receptor distribution of the two group I mGluRs. The Group II agonist LY354740 (1S,2S,5R,6S-2-aminobicycl[3.1.0]hexane-2,6-dicarboxylate monohydrate) and the group III agonist L-AP 4 (L-(+)-2-amino-4-phosphonobutyric acid) failed to alter the levels of [ 3H]IP. LY341495 (2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid) is a nM potent Group II antagonist. However, LY341495 has also been found to have μM potency in inhibiting mGluR1 and 5. The stimulation of [ 3H]PI hydrolysis by 1 μmol DHPG was dose-dependently blocked by co-administration of the mGluR antagonists, LY341495 at doses that are constant with an interaction at Group I mGluR's. Taken together these results suggest that stimulation of group I mGluRs results in measurable increases in PI hydrolysis in vivo. This method could be quite useful in determining the doses and routes of administration of agonists and antagonists that are required to interact with group I mGluRs.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/S0006-8993(99)01065-3</identifier><identifier>PMID: 10064844</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>London: Elsevier B.V</publisher><subject>Amino Acids - pharmacology ; Animals ; Biochemistry and metabolism ; Biological and medical sciences ; Brain Chemistry - physiology ; Central nervous system ; Cerebellum - enzymology ; CHPG ; Cycloleucine - analogs &amp; derivatives ; Cycloleucine - pharmacology ; DHPG ; Dose-Response Relationship, Drug ; Excitatory Amino Acid Antagonists - pharmacology ; Fundamental and applied biological sciences. Psychology ; Glycine - analogs &amp; derivatives ; Glycine - pharmacology ; Group I ; Hippocampus - enzymology ; Hydrolysis ; In vivo ; Injections, Intraventricular ; Male ; Metabotropic glutamate ; Neuroprotective Agents - pharmacology ; Phenylacetates - pharmacology ; Phosphatidyl inositol hydrolysis ; Phosphatidylinositols - metabolism ; Rats ; Rats, Sprague-Dawley ; Receptors, Metabotropic Glutamate - agonists ; Receptors, Metabotropic Glutamate - metabolism ; Resorcinols - pharmacology ; Tritium ; Type C Phospholipases - metabolism ; Vertebrates: nervous system and sense organs ; Xanthenes - pharmacology</subject><ispartof>Brain research, 1999-03, Vol.821 (2), p.539-545</ispartof><rights>1999 Elsevier Science B.V.</rights><rights>1999 INIST-CNRS</rights><rights>Copyright 1999 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-4cd17b080b021316e4ff75e13ec565baa27b761047fc8b8a825aedd96b897cf93</citedby><cites>FETCH-LOGICAL-c390t-4cd17b080b021316e4ff75e13ec565baa27b761047fc8b8a825aedd96b897cf93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0006-8993(99)01065-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1725552$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10064844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, Michael P</creatorcontrib><creatorcontrib>Chamberlain, Maryjo</creatorcontrib><creatorcontrib>Kelly, Gerard M</creatorcontrib><title>Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>The present report describes the effect of mGluR agonists and antagonists administration on phospholipase C activation by measuring accumulation of [ 3H] inositol monophosphates (IP) in rats pre-labeled with [ 3H] myo-inositol (i.c.v. 24 h pre-treatment). The levels of accumulated [ 3H]IP were then determined from clarified tissue homogenates using ion-exchange chromotography. Following lithium chloride treatment (10 mg/kg, s.c.), (R/S)-3,5-dihydroxyphenylglycine (DHPG), a selective group I mGluR agonist was found to dose-dependently cause a maximal increase in the levels of [ 3H]IP at 0.3 to 3 μmol/8 μl i.c.v. with lower doses resulting in less efficacious or no responses. This effect was temporal-dependent reaching a plateau at 2 h. The DHPG-induced increases in [ 3H]IP were most pronounced in the hippocampus where a 3- to 5-fold increase above vehicle was consistently found, but significant approximately 2-fold increases were also seen in the cerebellum, striatum and frontal cortex. The mixed group I and II agonist, (1S,3R)-1-aminocyclopentane- trans-1,3-dicarboxylic acid (1S,3R- t-ACPD), similarly resulted in dose-dependent increases in [ 3H]IP levels with doses of 1 to 3 μmol i.c.v. Furthermore, this effect was enantiomer specific since the less active 1R,3S- t-ACPD failed to alter phosphoinositol hydrolysis. Administration of the selective mGluR5 agonist (R/S)-2-chloro-5-hydroxyphenyl-glycine (CHPG) resulted in a dose-dependent increase in hippocampal but not cerebellar levels of [ 3H]IP, consistent with the receptor distribution of the two group I mGluRs. The Group II agonist LY354740 (1S,2S,5R,6S-2-aminobicycl[3.1.0]hexane-2,6-dicarboxylate monohydrate) and the group III agonist L-AP 4 (L-(+)-2-amino-4-phosphonobutyric acid) failed to alter the levels of [ 3H]IP. LY341495 (2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid) is a nM potent Group II antagonist. However, LY341495 has also been found to have μM potency in inhibiting mGluR1 and 5. The stimulation of [ 3H]PI hydrolysis by 1 μmol DHPG was dose-dependently blocked by co-administration of the mGluR antagonists, LY341495 at doses that are constant with an interaction at Group I mGluR's. Taken together these results suggest that stimulation of group I mGluRs results in measurable increases in PI hydrolysis in vivo. This method could be quite useful in determining the doses and routes of administration of agonists and antagonists that are required to interact with group I mGluRs.</description><subject>Amino Acids - pharmacology</subject><subject>Animals</subject><subject>Biochemistry and metabolism</subject><subject>Biological and medical sciences</subject><subject>Brain Chemistry - physiology</subject><subject>Central nervous system</subject><subject>Cerebellum - enzymology</subject><subject>CHPG</subject><subject>Cycloleucine - analogs &amp; derivatives</subject><subject>Cycloleucine - pharmacology</subject><subject>DHPG</subject><subject>Dose-Response Relationship, Drug</subject><subject>Excitatory Amino Acid Antagonists - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycine - analogs &amp; derivatives</subject><subject>Glycine - pharmacology</subject><subject>Group I</subject><subject>Hippocampus - enzymology</subject><subject>Hydrolysis</subject><subject>In vivo</subject><subject>Injections, Intraventricular</subject><subject>Male</subject><subject>Metabotropic glutamate</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Phenylacetates - pharmacology</subject><subject>Phosphatidyl inositol hydrolysis</subject><subject>Phosphatidylinositols - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Metabotropic Glutamate - agonists</subject><subject>Receptors, Metabotropic Glutamate - metabolism</subject><subject>Resorcinols - pharmacology</subject><subject>Tritium</subject><subject>Type C Phospholipases - metabolism</subject><subject>Vertebrates: nervous system and sense organs</subject><subject>Xanthenes - pharmacology</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EotvCTwD5gFA5BOw4tuNThSo-KlUCCThwshxnsmuUxMHjLNp_j9tdATdOo9E8M_PqIeQZZ6854-rNF8aYqlpjxKUxrxhnSlbiAdnwVteVqhv2kGz-IGfkHPFHaYUw7DE542XQtE2zId8_7yIuuxjmiCGHHuju0Kc4HjAgDTPdh32kv0Le0W2K60Jv6ATZdTGnuARPt-Oa3eQy0AQelhwTdds4B8z4hDwa3Ijw9FQvyLf3775ef6xuP324uX57W_mSJVeN77nuWMs6VnPBFTTDoCVwAV4q2TlX604rzho9-LZrXVtLB31vVNca7QcjLsjL490lxZ8rYLZTQA_j6GaIK1plFNOCqQLKI-hTREww2CWFyaWD5czeObX3Tu2dMGuMvXdqRdl7fnqwdhP0_2wdJRbgxQlw6N04JDf7gH85XUsp64JdHTEoNvYBkkUfYPbQhyIv2z6G_yT5DQxllN4</recordid><startdate>19990313</startdate><enddate>19990313</enddate><creator>Johnson, Michael P</creator><creator>Chamberlain, Maryjo</creator><creator>Kelly, Gerard M</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990313</creationdate><title>Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists</title><author>Johnson, Michael P ; Chamberlain, Maryjo ; Kelly, Gerard M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-4cd17b080b021316e4ff75e13ec565baa27b761047fc8b8a825aedd96b897cf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Amino Acids - pharmacology</topic><topic>Animals</topic><topic>Biochemistry and metabolism</topic><topic>Biological and medical sciences</topic><topic>Brain Chemistry - physiology</topic><topic>Central nervous system</topic><topic>Cerebellum - enzymology</topic><topic>CHPG</topic><topic>Cycloleucine - analogs &amp; derivatives</topic><topic>Cycloleucine - pharmacology</topic><topic>DHPG</topic><topic>Dose-Response Relationship, Drug</topic><topic>Excitatory Amino Acid Antagonists - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycine - analogs &amp; derivatives</topic><topic>Glycine - pharmacology</topic><topic>Group I</topic><topic>Hippocampus - enzymology</topic><topic>Hydrolysis</topic><topic>In vivo</topic><topic>Injections, Intraventricular</topic><topic>Male</topic><topic>Metabotropic glutamate</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Phenylacetates - pharmacology</topic><topic>Phosphatidyl inositol hydrolysis</topic><topic>Phosphatidylinositols - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Metabotropic Glutamate - agonists</topic><topic>Receptors, Metabotropic Glutamate - metabolism</topic><topic>Resorcinols - pharmacology</topic><topic>Tritium</topic><topic>Type C Phospholipases - metabolism</topic><topic>Vertebrates: nervous system and sense organs</topic><topic>Xanthenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, Michael P</creatorcontrib><creatorcontrib>Chamberlain, Maryjo</creatorcontrib><creatorcontrib>Kelly, Gerard M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, Michael P</au><au>Chamberlain, Maryjo</au><au>Kelly, Gerard M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1999-03-13</date><risdate>1999</risdate><volume>821</volume><issue>2</issue><spage>539</spage><epage>545</epage><pages>539-545</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>The present report describes the effect of mGluR agonists and antagonists administration on phospholipase C activation by measuring accumulation of [ 3H] inositol monophosphates (IP) in rats pre-labeled with [ 3H] myo-inositol (i.c.v. 24 h pre-treatment). The levels of accumulated [ 3H]IP were then determined from clarified tissue homogenates using ion-exchange chromotography. Following lithium chloride treatment (10 mg/kg, s.c.), (R/S)-3,5-dihydroxyphenylglycine (DHPG), a selective group I mGluR agonist was found to dose-dependently cause a maximal increase in the levels of [ 3H]IP at 0.3 to 3 μmol/8 μl i.c.v. with lower doses resulting in less efficacious or no responses. This effect was temporal-dependent reaching a plateau at 2 h. The DHPG-induced increases in [ 3H]IP were most pronounced in the hippocampus where a 3- to 5-fold increase above vehicle was consistently found, but significant approximately 2-fold increases were also seen in the cerebellum, striatum and frontal cortex. The mixed group I and II agonist, (1S,3R)-1-aminocyclopentane- trans-1,3-dicarboxylic acid (1S,3R- t-ACPD), similarly resulted in dose-dependent increases in [ 3H]IP levels with doses of 1 to 3 μmol i.c.v. Furthermore, this effect was enantiomer specific since the less active 1R,3S- t-ACPD failed to alter phosphoinositol hydrolysis. Administration of the selective mGluR5 agonist (R/S)-2-chloro-5-hydroxyphenyl-glycine (CHPG) resulted in a dose-dependent increase in hippocampal but not cerebellar levels of [ 3H]IP, consistent with the receptor distribution of the two group I mGluRs. The Group II agonist LY354740 (1S,2S,5R,6S-2-aminobicycl[3.1.0]hexane-2,6-dicarboxylate monohydrate) and the group III agonist L-AP 4 (L-(+)-2-amino-4-phosphonobutyric acid) failed to alter the levels of [ 3H]IP. LY341495 (2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid) is a nM potent Group II antagonist. However, LY341495 has also been found to have μM potency in inhibiting mGluR1 and 5. The stimulation of [ 3H]PI hydrolysis by 1 μmol DHPG was dose-dependently blocked by co-administration of the mGluR antagonists, LY341495 at doses that are constant with an interaction at Group I mGluR's. Taken together these results suggest that stimulation of group I mGluRs results in measurable increases in PI hydrolysis in vivo. This method could be quite useful in determining the doses and routes of administration of agonists and antagonists that are required to interact with group I mGluRs.</abstract><cop>London</cop><cop>Amsterdam</cop><cop>New York, NY</cop><pub>Elsevier B.V</pub><pmid>10064844</pmid><doi>10.1016/S0006-8993(99)01065-3</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-8993
ispartof Brain research, 1999-03, Vol.821 (2), p.539-545
issn 0006-8993
1872-6240
language eng
recordid cdi_proquest_miscellaneous_69607306
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Amino Acids - pharmacology
Animals
Biochemistry and metabolism
Biological and medical sciences
Brain Chemistry - physiology
Central nervous system
Cerebellum - enzymology
CHPG
Cycloleucine - analogs & derivatives
Cycloleucine - pharmacology
DHPG
Dose-Response Relationship, Drug
Excitatory Amino Acid Antagonists - pharmacology
Fundamental and applied biological sciences. Psychology
Glycine - analogs & derivatives
Glycine - pharmacology
Group I
Hippocampus - enzymology
Hydrolysis
In vivo
Injections, Intraventricular
Male
Metabotropic glutamate
Neuroprotective Agents - pharmacology
Phenylacetates - pharmacology
Phosphatidyl inositol hydrolysis
Phosphatidylinositols - metabolism
Rats
Rats, Sprague-Dawley
Receptors, Metabotropic Glutamate - agonists
Receptors, Metabotropic Glutamate - metabolism
Resorcinols - pharmacology
Tritium
Type C Phospholipases - metabolism
Vertebrates: nervous system and sense organs
Xanthenes - pharmacology
title Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A02%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phosphoinositide%20hydrolysis%20in%20vivo%20with%20group%20I%20metabotropic%20glutamate%20receptor%20agonists&rft.jtitle=Brain%20research&rft.au=Johnson,%20Michael%20P&rft.date=1999-03-13&rft.volume=821&rft.issue=2&rft.spage=539&rft.epage=545&rft.pages=539-545&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/S0006-8993(99)01065-3&rft_dat=%3Cproquest_cross%3E69607306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69607306&rft_id=info:pmid/10064844&rft_els_id=S0006899399010653&rfr_iscdi=true